1. Home
  2. ASBP vs MBRX Comparison

ASBP vs MBRX Comparison

Compare ASBP & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aspire Biopharma Holdings Inc.

ASBP

Aspire Biopharma Holdings Inc.

HOLD

Current Price

$8.95

Market Cap

12.4M

Sector

Health Care

ML Signal

HOLD

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

HOLD

Current Price

$0.78

Market Cap

12.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASBP
MBRX
Founded
2021
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.4M
12.7M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
ASBP
MBRX
Price
$8.95
$0.78
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$61.00
AVG Volume (30 Days)
24.1K
759.8K
Earning Date
04-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.16
52 Week High
$9.50
$7.98

Technical Indicators

Market Signals
Indicator
ASBP
MBRX
Relative Strength Index (RSI) 63.66 45.85
Support Level $4.63 $0.26
Resistance Level N/A $2.26
Average True Range (ATR) 0.49 0.07
MACD 0.04 0.08
Stochastic Oscillator 70.53 92.03

Price Performance

Historical Comparison
ASBP
MBRX

About ASBP Aspire Biopharma Holdings Inc.

Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: